The Medicines Co.'s new CEO Mark Timney took over the helm in December to execute a straightforward business plan: shepherd the RNAi therapeutic inclisiran successfully through Phase III development and find a buyer for the cholesterol lowering medicine.
The Medicines Co. CEO Timney On Selling Inclisiran And Why Big Pharma Is Still Interested In CV Disease
Mark Timney took over the helm at The Medicines Company in December with a singular focus: wrapping up the Phase III program for inclisiran and finding a buyer for the cholesterol-lowering drug.
